We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Evolocumab (Repatha)is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Evolocumab (Repatha) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2015–2022 with a typical study size of 27,564 participants.
Based on 7 studies · 5 RCTs · 27,564 total participants
Confidence
HighBy outcome
Evolocumab (Repatha) has an evidence score of 4.5/10 — strong evidence based on 7 indexed studies, including 1 meta-analysis. A prescription PCSK9-inhibitor monoclonal antibody (Repatha) given by subcutaneous injection. By binding circulating PCSK9 it spares LDL receptors and lowers LDL cholesterol by roughly 60%. The landmark FOURIER trial in ~27,500 statin-treated patients showed it cut cardiovascular events, and it produces dramatic LDL lowering in familial hypercholesterolemia. Very safe apart from injection-site reactions; cost and injection burden are the main trade-offs. A prescription drug, not a supplement. Representative study: PMID 33078867.
The commonly studied dose of Evolocumab (Repatha) is Standard approved dosing is 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly, under a clinician. A prescription drug; this is informational, not a recommendation.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Nicotinamide Riboside
Mostly mechanism / observationalA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
Alirocumab (Praluent)
Notable regimens that report including Evolocumab (Repatha) — documented, not endorsed.
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Evolocumab (Repatha) — PCSK9-inhibitor monoclonal antibody
A prescription PCSK9-inhibitor monoclonal antibody (Repatha) given by subcutaneous injection. By binding circulating PCSK9 it spares LDL receptors and lowers LDL cholesterol by roughly 60%. The landmark FOURIER trial in ~27,500 statin-treated patients showed it cut cardiovascular events, and it produces dramatic LDL lowering in familial hypercholesterolemia. Very safe apart from injection-site reactions; cost and injection burden are the main trade-offs. A prescription drug, not a supplement.
Evolocumab has strong randomized evidence: FOURIER (~27,500 patients) showed reduced cardiovascular events on top of statins, GLAGOV showed coronary plaque regression, and it lowers LDL-C by ~60% including in familial hypercholesterolemia. It is very safe apart from injection-site reactions. The trade-offs that keep it short of the top are high cost/access barriers and injection burden — and there is no demonstrated general longevity benefit beyond cardiovascular event reduction.
Evolocumab is a fully human monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9).
PCSK9 normally binds LDL receptors on the liver and routes them for degradation; by neutralizing circulating PCSK9, evolocumab lets LDL receptors recycle back to the cell surface and clear more LDL cholesterol from the blood — lowering LDL-C by approximately 60%, on top of statins.
It is delivered by subcutaneous injection (140 mg every two weeks or 420 mg monthly).
The cardiovascular-outcomes case is unusually strong for a lipid drug: in FOURIER (Sabatine et al., 2017, ~27,500 statin-treated patients with atherosclerotic disease) evolocumab significantly reduced major cardiovascular events, and the FOURIER open-label extension (FOURIER-OLE) suggested continued and possibly growing benefit with longer exposure.
In imaging, the GLAGOV trial showed regression of coronary atherosclerotic plaque, and in heterozygous familial hypercholesterolemia (RUTHERFORD-2) it produced large LDL reductions in patients who cannot reach goal on statins alone. It is also used in statin-intolerant patients (GAUSS-3).
The honest framing: the proven outcome is fewer cardiovascular events and dramatic LDL lowering — there is no demonstrated general 'longevity' or lifespan benefit, and the trade-offs are real: high cost and access barriers, an injection burden, the theoretical immunogenicity of any antibody, and injection-site reactions.
Very low achieved LDL levels have not shown clear harm in trials to date. Evolocumab is a prescription drug; this is an informational entry, not a recommendation — lipid-lowering therapy must be directed by a clinician.
The score reflects genuinely strong randomized cardiovascular-outcome and LDL-lowering data against the cost, access, and injection trade-offs of a specialist drug.
Binds circulating PCSK9 so it can no longer mark LDL receptors for degradation, the antibody's core action.
With PCSK9 blocked, hepatic LDL receptors recycle back to the cell surface and clear far more LDL cholesterol from the blood.
Sustained ~60% LDL lowering on top of statins slows or regresses atherosclerotic plaque and reduces cardiovascular events.
How Evolocumab (Repatha) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Standard approved dosing is 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly, under a clinician. A prescription drug; this is informational, not a recommendation.
Loading: No loading dose; either the every-2-week (140 mg) or once-monthly (420 mg) regimen is chosen at initiation.
Can be taken without food
| Form | Type |
|---|---|
| 💊Subcutaneous prefilled autoinjector (evolocumab) | Recommended |
| 💊Alirocumab (same PCSK9-inhibitor antibody class) | Alternative |
| 💊Inclisiran (PCSK9-targeting siRNA, different modality) | Alternative |
Evolocumab has the FOURIER cardiovascular-outcome and GLAGOV plaque-regression data; alirocumab is a same-class antibody with its own outcomes trial.
Compare Evolocumab (Repatha) vs Alirocumab (Praluent) →Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: Inject subcutaneously every 2 weeks (140 mg) or monthly (420 mg); rotate sites and continue background lipid therapy as directed.
Dose-response data unavailable. The current published research for Evolocumab (Repatha) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Lowers LDL cholesterol by roughly 60% on top of statin therapy, with LDL often reaching very low levels.
FOURIER showed significantly fewer major cardiovascular events in statin-treated patients with atherosclerotic disease.
Produces dramatic LDL lowering in heterozygous familial hypercholesterolemia, where statins alone often fall short.
Subcutaneous injection every 2 weeks or monthly; injection-site reactions can occur, and cost/access barriers and antibody immunogenicity are real trade-offs.
A primary indication — large LDL reductions where statins alone fall short, under specialist care.
Studied (GAUSS-3) as an option when statins are not tolerated, directed by a clinician.
Limited human data; antibodies cross the placenta in later pregnancy — discuss with a clinician and generally avoid.
Intentionally combined — additive LDL lowering; this is the studied use, not an adverse interaction.
Often layered for additive LDL lowering; no harmful interaction, used together by design.
Tip: Redness, pain, or bruising at the site; rotate injection sites and let the pen reach room temperature first.
Tip: Mild cold-like symptoms reported in trials; usually self-limited.
Tip: As with any monoclonal antibody, allergic reactions and anti-drug antibodies are possible; seek care for rash, swelling, or breathing difficulty.
Timing is flexible for Evolocumab (Repatha) — consistent daily use matters more than the time of day. A subcutaneous antibody injection; timing of day is not critical.
Evolocumab (Repatha) is generally safe at recommended doses, with a few precautions worth noting. The most commonly reported side effects are injection-site reactions, nasopharyngitis / upper-respiratory symptoms, hypersensitivity / antibody response. Use caution if any of these apply to you: Prior serious hypersensitivity reaction to evolocumab; Use only under clinician direction as part of a lipid-management plan.
A fully human monoclonal-antibody PCSK9 inhibitor (Praluent), injected under the skin every 2 weeks, that lowers LDL cholesterol by ~50–60%. In the ODYSSEY OUTCOMES trial of ~18,900 post-heart-attack patients it reduced major cardiovascular events and showed a possible all-cause mortality signal. Generally well tolerated; injection-site reactions and high cost/access are the main trade-offs. Prescription drug, not a supplement.